Spots Global Cancer Trial Database for elacestrant
Every month we try and update this database with for elacestrant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | NCT05618613 | Breast Cancer | Elacestrant Onapristone | 18 Years - | Context Therapeutics Inc. | |
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Elacestrant in Preoperative Setting, a Window of Opportunity Study | NCT04797728 | Breast Cancer Hormone Recepto... | Elacestrant | 18 Years - | SOLTI Breast Cancer Research Group | |
| A Pharmacokinetic Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function | NCT06126575 | Hepatic Impairm... | Elacestrant dih... | 18 Years - | Stemline Therapeutics, Inc. | |
| Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer | NCT03778931 | Breast Cancer | Elacestrant Standard of Car... | 18 Years - | Stemline Therapeutics, Inc. | |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | NCT06075953 | Ductal Carcinom... | Tamoxifen Exemestane Letrozole Anastrazole Testosterone + ... Elacestrant Z-endoxifen | 18 Years - | QuantumLeap Healthcare Collaborative | |
| A Pharmacokinetic Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function | NCT06126575 | Hepatic Impairm... | Elacestrant dih... | 18 Years - | Stemline Therapeutics, Inc. | |
| ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | NCT05596409 | Metastatic Brea... | Elacestrant | 18 Years - | Stemline Therapeutics, Inc. | |
| Elacestrant in Preoperative Setting, a Window of Opportunity Study | NCT04797728 | Breast Cancer Hormone Recepto... | Elacestrant | 18 Years - | SOLTI Breast Cancer Research Group | |
| A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer | NCT02338349 | Advanced ER+, H... | Elacestrant | 18 Years - | Stemline Therapeutics, Inc. | |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer | NCT05563220 | Breast Cancer Metastatic Brea... | Elacestrant Alpelisib Everolimus Ribociclib Palbociclib Capivasertib Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | NCT05512364 | ER-positive Bre... HER2-negative B... Stage IIB Breas... Stage III Breas... | Elacestrant Tamoxifen Letrozole 2.5mg Anastrozole 1mg Exemestane 25 M... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | NCT05982093 | Breast Cancer HER2-negative B... Hormone Recepto... Premenopausal B... | Elacestrant Triptorelin | 35 Years - | SOLTI Breast Cancer Research Group | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | NCT05512364 | ER-positive Bre... HER2-negative B... Stage IIB Breas... Stage III Breas... | Elacestrant Tamoxifen Letrozole 2.5mg Anastrozole 1mg Exemestane 25 M... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | NCT05618613 | Breast Cancer | Elacestrant Onapristone | 18 Years - | Context Therapeutics Inc. | |
| A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer | NCT02338349 | Advanced ER+, H... | Elacestrant | 18 Years - | Stemline Therapeutics, Inc. | |
| Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer | NCT04791384 | Breast Cancer | Abemaciclib Elacestrant | 18 Years - | Criterium, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
